Follow the people · Insider
Corey Michael Watton
Corey Michael Watton files insider transactions with the SEC as a director of Zevra Therapeutics (ZVRA). We hold 1 disclosed purchase or sale filed since 8 May 2023, 1 of them in the last 90 days.
- Files forZVRA
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 May 2023 — 10 August 2026Director · Zevra Therapeutics (ZVRA)12 Form 4 lines · source: SEC Form 4
Everything they disclosed
12 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 12,300 shares of Zevra TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 12,300 shares of Zevra TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- exercised options over 12,300 shares of Zevra Therapeutics (a derivative holding)SEC Form 412 August 2026Stock Option (right to buy) · traded 10 August 2026 · filed 12 August 2026
- was granted 30,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 418 June 2026Stock Option (right to buy) · traded 4 June 2026 · filed 18 June 2026
- was granted 30,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (right to buy) · traded 29 May 2025 · filed 30 May 2025
- ▲ bought on the open market 300 shares of Zevra TherapeuticsSEC Form 431 March 2025Common Stock · traded 28 March 2025 · filed 31 March 2025
- ▲ bought on the open market 500 shares of Zevra TherapeuticsSEC Form 416 October 2024Common Stock · traded 11 October 2024 · filed 16 October 2024
- was granted 39,200 shares of Zevra Therapeutics (a derivative holding)SEC Form 415 May 2024Stock Option (right to buy) · traded 13 May 2024 · filed 15 May 2024
- ▲ bought on the open market 275 shares of Zevra TherapeuticsSEC Form 426 June 2023Common Stock · traded 23 June 2023 · filed 26 June 2023
- ▲ bought on the open market 325 shares of Zevra TherapeuticsSEC Form 413 June 2023Common Stock · traded 9 June 2023 · filed 13 June 2023
- ▲ bought on the open market 400 shares of Zevra TherapeuticsSEC Form 431 May 2023Common Stock · traded 30 May 2023 · filed 31 May 2023
- was granted 58,800 shares of Zevra Therapeutics (a derivative holding)SEC Form 48 May 2023Stock Option (right to buy) · traded 3 May 2023 · filed 8 May 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.